Meticulous Research®, a leading global market research firm, has released a comprehensive report titled, “RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast to 2029.” This publication reveals significant insights into the real-world evidence (RWE) oncology solutions market, projecting substantial growth over the next several years.
According to the report, the RWE oncology solutions market
is anticipated to expand at a compound annual growth rate (CAGR) of 14.2% from
2022 to 2029, ultimately reaching a market value of $1.65 billion by 2029.
Several factors are driving this growth, including the increasing prevalence of
cancer, the rapid expansion of big data within healthcare, a transition from
volume-based to value-based care, and a heightened emphasis on personalized
healthcare approaches. Despite this positive outlook, the market faces
challenges, particularly the lack of standardized methodologies for developing
RWE.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5276?utm_source=article&utm_medium=Social&utm_campaign=Product&utm_content=03-10-2024
The report categorizes the RWE oncology solutions market by
components, applications, end users, and geographic regions. In terms of
components, the market is divided into real-world datasets and RWE consulting
and analytics services. The real-world datasets segment is expected to hold the
largest market share in 2022, fueled by the growing volume of medical data
generated in healthcare settings. This data is crucial for outcome-based
studies and is increasingly sought after by payers, regulatory bodies, and
providers looking to ensure drug safety.
Applications of RWE in oncology are diverse, with the drug
development and approvals segment projected to account for the largest share in
2022. Metrics related to quality of life and Patient-Reported Outcome Measures
(PROMs) are becoming integral to clinical trials, enhancing the understanding
of disease epidemiology and treatment pathways. The increasing incidence of
cancer has spurred pharmaceutical companies to prioritize drug development,
with RWE serving as a vital tool to expedite discovery, facilitate drug
approvals, and assess the impact of new therapies.
End users of RWE oncology solutions primarily include
pharmaceutical and medical device companies, which are expected to dominate the
market. This trend stems from the rising necessity for RWE studies in drug
development and the need to mitigate the risks associated with drug recalls by
evaluating real-world performance. As the healthcare landscape shifts, these
companies are increasingly leveraging RWE to gain insights into actual clinical
practices and health outcomes, allowing for more effective cancer treatments.
The report also offers an in-depth geographical analysis,
covering major regions such as North America (including the U.S. and Canada),
Asia-Pacific (encompassing Japan, China, India, and others), Europe (including
Germany, France, the U.K., and more), Latin America, and the Middle East &
Africa. This comprehensive analysis provides valuable insights into market
dynamics across different regions, offering a well-rounded perspective on the
RWE oncology solutions landscape leading up to 2029.
